Brighter Prospects Expected Ahead - Report on ImmuCell Corp.

Aug 06, 2015, 09:15 ET from

NEW YORK, August 6, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on ImmuCell Corp. (NASDAQ: ICCC). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL:

Highlights from our ICCC Report include:

  • Revised Sales Guidance - On July 08, 2015, ImmuCell Corporation announced that it is improving its product sales forecast guidance for the second quarter of 2015. The Company now expects its product sales to increase in the range of 25% to 30%, in comparison to the second quarter of 2014, from the previously announced anticipated decrease in the range of 15% to 20. This would amount to product sales the range of $1.93 to $2.0 million for Q2 2015, computed on the reported Q2 2014 sales figure of $1.54 million.
  • Better than Expected Inventory Production Leads to Upward Revision - Michael F. Brigham, President and CEO of ImmuCell Corporation said that the increase in guidance was primarily due to a better-than-expected inventory production schedule which allows the Company to address a portion of the pent-up demand that is building for First Defense®. He added that despite shipping of all the First Defense® that the Company can produce, it still faces a backlog of orders waiting to be shipped aggregating approximately $1.45 million as of June 30, 2015 vis-a-vis $1.28 million as of March 31, 2015.
  • Management Commentary - The CEO said that the Company remains on track to complete all of its planned manufacturing capacity expansion investments by Q1 of fiscal 2016. He further stated that the Company expects year-to-date product sales to be approximately 40% higher than the first six months of 2014 and it continues to expect positive year-to-date sales growth throughout 2015, in comparison to the same periods in 2014.
  • Snapshot of the Most Recent Quarter - The Company had reported sales of $3.1 million for Q1 FY15 up 49% on a y-o-y basis. It was the Company's eleventh consecutive quarter of positive sales growth. During Q1, sales of First Defense® had come in at $2.98 million, surpassing 15 million units since the product was launched by the Company in 1991. Net income for Q1 was $0.48 million or 15 cents per diluted share.
  • Q2 FY14 Summary - During second quarter of the previous fiscal, the Company had generated $1.54 million in product sales, thereby clocking a growth of 13% on a y-o-y basis. It was the Company's eight consecutive quarter of sales growth. The growth in product sales was driven by increased acceptance of the Company's First Defense® product line for the prevention of calf scours. Gross margins for Q2 FY14 were reported to be 57% of product sales.

To find out how this influences our rating on ImmuCell Corp. read the full report in its entirety here:

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.